1. Scrip
  2. >>COVID-19

Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways

Collaborations, Agility Also Key

 
• By Anju Ghangurde

Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.

Amgen
Amgen chief signals opportunities to accelerate drug development • Source: Alamy

There have been lots of expert voices around pandemic-related learnings and regulatory adjustments that have the potential to stick as the world seeks to crawl back to some semblance of normalcy as COVID-19 vaccination gathers pace.

Amgen, Inc. CEO Robert Bradway found himself on tricky terrain on the issue at the recent USA-India Chamber of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Executives On The Move: Instylla And Geron Get New CEOs

Recent moves in the industry include changes at the top at Meitheal Pharmaceuticals, Ardelyx and AIRNA, plus five companies get new CMOs.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead

 
• By Mandy Jackson

Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.